EGFR and non-small cell lung carcinoma: Compared with standard EGFR‐TKIs, Osimertinib performed better progression‐free survival (PFS) than comparator EGFR‐TKIs (18.9 months vs. 10.2 months) in the FLAURA trial involving patients with previously untreated EGFR‐mutated advanced NSCLC.4, 5